|
|
|
|
|||||
|
|
|
Microbot Medical Inc. (NASDAQ:MBOT) is one of the best-performing NASDAQ stocks according to analysts. On June 17, Microbot Medical announced that it had been granted a patent in China by the China National Intellectual Property Administration/CNIPA.
The patent covers the robotic manipulation of a surgical tool handle and is a step in the company’s global intellectual property/IP expansion strategy. LIBERTY System now includes 9 patents granted globally and 59 patent applications pending. The LIBERTY system is a single-use and fully disposable endovascular robotic system for assisting surgeons in performing minimally invasive procedures within blood vessels.
The patent portfolio protects the capabilities of the LIBERTY System. Microbot Medical’s focus remains on the US market, where it is preparing for the anticipated commercial launch of the LIBERTY Endovascular Robotic System in Q3 2025.
Microbot Medical Inc. (NASDAQ:MBOT) is a clinical-stage medical device company that researches, designs, and develops robotic endoluminal surgery devices targeting the minimally invasive surgery space in Israel and the US.
While we acknowledge the potential of MBOT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| Jul-09 | |
| Jul-08 | |
| Jun-30 | |
| Jun-17 | |
| Jun-12 | |
| Jun-09 | |
| Jun-09 | |
| Jun-05 | |
| Apr-23 | |
| Apr-18 | |
| Apr-15 | |
| Apr-10 | |
| Apr-09 | |
| Apr-01 | |
| Mar-04 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite